Welcome to STN International! Enter x:x LOGINID: SSPTALDB1623 PASSWORD: TERMINAL (ENTER 1, 2, 3, OR ?):2 * * * * * * * * * * Welcome to STN International Web Page for STN Seminar Schedule - N. America NEWS 2 JAN 02 STN pricing information for 2008 now available NEWS 3 JAN 16 CAS patent coverage enhanced to include exemplified prophetic substances NEWS 4 JAN 28 USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats NEWS 5 JAN 28 MARPAT searching enhanced NEWS 6 JAN 28 USGENE now provides USPTO sequence data within 3 days of publication NEWS 7 JAN 28 TOXCENTER enhanced with reloaded MEDLINE segment NEWS 8 JAN 28 MEDLINE and LMEDLINE reloaded with enhancements NEWS 9 FEB 08 STN Express, Version 8.3, now available NEWS 10 FEB 20 PCI now available as a replacement to DPCI NEWS 11 FEB 25 IFIREF reloaded with enhancements NEWS 12 FEB 25 IMSPRODUCT reloaded with enhancements NEWS 13 FEB 29 WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification NEWS 14 MAR 31 IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats NEWS 15 MAR 31 CAS REGISTRY enhanced with additional experimental spectra NEWS 16 MAR 31 CA/Caplus and CASREACT patent number format for U.S. applications updated NEWS 17 MAR 31 LPCI now available as a replacement to LDPCI NEWS 18 MAR 31 EMBASE, EMBAL, and LEMBASE reloaded with enhancements NEWS 19 APR 04 STN AnaVist, Version 1, to be discontinued NEWS 20 APR 15 WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats NEWS 21 APR 28 EMBASE Controlled Term thesaurus enhanced NEWS 22 APR 28 IMSRESEARCH reloaded with enhancements NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3, AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008 NEWS HOURS STN Operating Hours Plus Help Desk Availability

Enter NEWS followed by the item number or name to see news on that specific topic.

Welcome Banner and News Items

NEWS LOGIN NEWS IPC8

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation

For general information regarding STN implementation of IPC 8

of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 13:24:42 ON 28 APR 2008

=> file caplus
COST IN U.S. DOLLARS

SINCE FILE TOTAL
ENTRY SESSION
0.21 0.21

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 13:24:55 ON 28 APR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 28 Apr 2008 VOL 148 ISS 18 FILE LAST UPDATED: 27 Apr 2008 (20080427/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

=> e bovin	nicolai	/au	
E1	8	BOVIN	N I/AU
E2	172	BOVIN	N V/AU
E3	34>	BOVIN	NICOLAI/AU
E4	1	BOVIN	NICOLAI N/AU
E5	71	BOVIN	NICOLAI V/AU
E6	2	BOVIN	NICOLAI VLADIMIROVICH/AU
E7	4	BOVIN	NIKOLAI/AU
E8	6	BOVIN	NIKOLAI V/AU
E9	1	BOVIN	NIKOLAI VLADIMIROVICH/AU
E10	3	BOVIN	NIKOLAJ V/AU
E11	1	BOVIN	NIKOLAY/AU
E12	1	BOVIN	NIKOLAY V/AU
=> e			
E13	2	BOVIN	NIKOLAY VLADIMIROVICH/AU
E14	1	BOVIN	PIERRE/AU
E15	4	BOVIN	S A/AU
E16	1	BOVIN	U P/AU
E17	20	BOVIN	V P/AU
E18	1	BOVIN	V V/AU
E19	6	BOVIN	YU P/AU
E20	47	BOVINA	A A F/AU
E21	1	BOVINA	A A V/AU

```
BOVINA ASYA
BOVINA C/AU
BOVINA
E22
           1
                 BOVINA ASYA F/AU
E23
          39
E24
           34
                 BOVINA CARLA/AU
=> s e1-e13
            8 "BOVIN N I"/AU
           172 "BOVIN N V"/AU
           34 "BOVIN NICOLAI"/AU
            1 "BOVIN NICOLAI N"/AU
           71 "BOVIN NICOLAI V"/AU
            2 "BOVIN NICOLAI VLADIMIROVICH"/AU
            4 "BOVIN NIKOLAI"/AU
            6 "BOVIN NIKOLAI V"/AU
            1 "BOVIN NIKOLAI VLADIMIROVICH"/AU
            3 "BOVIN NIKOLAJ V"/AU
            1 "BOVIN NIKOLAY"/AU
            1 "BOVIN NIKOLAY V"/AU
            2 "BOVIN NIKOLAY VLADIMIROVICH"/AU
           306 ("BOVIN N I"/AU OR "BOVIN N V"/AU OR "BOVIN NICOLAI"/AU OR "BOVI
L1
              N NICOLAI N"/AU OR "BOVIN NICOLAI V"/AU OR "BOVIN NICOLAI VLADIM
               IROVICH"/AU OR "BOVIN NIKOLAI"/AU OR "BOVIN NIKOLAI V"/AU OR
               "BOVIN NIKOLAI VLADIMIROVICH"/AU OR "BOVIN NIKOLAJ V"/AU OR "BOV
              IN NIKOLAY"/AU OR "BOVIN NIKOLAY V"/AU OR "BOVIN NIKOLAY VLADIMI
              ROVICH"/AU)
=> e gilliver lissa/au
E1
            4 GILLIVER K/AU
E2
            1
                 GILLIVER L G/AU
            1 --> GILLIVER LISSA/AU
E3
                GILLIVER LISSA GWYNETH/AU
E4
            3
Е5
            1
                  GILLIVER LOUISE/AU
                 GILLIVER MERV/AU
Ε6
            1
                 GILLIVER MOIRA A/AU
E7
            1
E8
           1
                 GILLIVER P J/AU
                 GILLIVER PETER J/AU
E9
           1
           1
                 GILLIVER S C/AU
E10
                GILLIVER STEPHEN C/AU
E11
            4
E12
                 GILLIVRAY W A/AU
=> s e2-e3
            1 "GILLIVER L G"/AU
             1 "GILLIVER LISSA"/AU
L2
            2 ("GILLIVER L G"/AU OR "GILLIVER LISSA"/AU)
=> e henry stephen/au
            1 HENRY STANLEY MICHELLE JENNEE/AU
                 HENRY STEPHANIE/AU
E_2
           17 --> HENRY STEPHEN/AU
EЗ
               HENRY STEPHEN F/AU
E4
            1
                HENRY STEPHEN G/AU
            3
E.5
                 HENRY STEPHEN M/AU
Ε6
            6
E7
                 HENRY STEPHEN MICHAEL/AU
            4
Ε8
            1
                 HENRY STEPHEN MICHEAL/AU
                 HENRY STEPHEN P/AU
Ε9
            3
                 HENRY STEPHEN PHILIP/AU
E10
            1
            4
                 HENRY STEVE/AU
E11
E12
            2
                 HENRY STEVEN/AU
```

=> s e3-e10

```
3 "HENRY STEPHEN G"/AU
              6 "HENRY STEPHEN M"/AU
              4 "HENRY STEPHEN MICHAEL"/AU
              1 "HENRY STEPHEN MICHEAL"/AU
              3 "HENRY STEPHEN P"/AU
              1 "HENRY STEPHEN PHILIP"/AU
L3
             36 ("HENRY STEPHEN"/AU OR "HENRY STEPHEN F"/AU OR "HENRY STEPHEN
                G"/AU OR "HENRY STEPHEN M"/AU OR "HENRY STEPHEN MICHAEL"/AU OR
                "HENRY STEPHEN MICHEAL"/AU OR "HENRY STEPHEN P"/AU OR "HENRY
                STEPHEN PHILIP"/AU)
=> e korchagina elena/au
                 KORCHAGINA E Y/AU
             5
E.2
             14
                   KORCHAGINA E YU/AU
Е3
             6 --> KORCHAGINA ELENA/AU
E4
            13
                   KORCHAGINA ELENA Y/AU
                   KORCHAGINA ELENA YU/AU
E5
             2
            2 KORCHAGINA ELENA 1U/AU
2 KORCHAGINA ELENA YURIEVNA/AU
12 KORCHAGINA G A/AU
5 KORCHAGINA G K/AU
5 KORCHAGINA G P/AU
8 KORCHAGINA G T/AU
2 KORCHAGINA G V/AU
1 KORCHAGINA GALINA T/AU
Ε6
            12
E7
Ε8
E9
E10
E11
E12
             1
                   KORCHAGINA GALINA T/AU
=> s e1-e6
              5 "KORCHAGINA E Y"/AU
             14 "KORCHAGINA E YU"/AU
              6 "KORCHAGINA ELENA"/AU
             13 "KORCHAGINA ELENA Y"/AU
              2 "KORCHAGINA ELENA YU"/AU
              2 "KORCHAGINA ELENA YURIEVNA"/AU
L4
             42 ("KORCHAGINA E Y"/AU OR "KORCHAGINA E YU"/AU OR "KORCHAGINA ELEN
                A"/AU OR "KORCHAGINA ELENA Y"/AU OR "KORCHAGINA ELENA YU"/AU OR
                "KORCHAGINA ELENA YURIEVNA"/AU)
=> 11 or 12 or 13 or 14
            343 L1 OR L2 OR L3 OR L4
L5
=> s 15 and antigen
        335182 ANTIGEN
         263586 ANTIGENS
         422387 ANTIGEN
                   (ANTIGEN OR ANTIGENS)
L6
             71 L5 AND ANTIGEN
=> 16 and (carbohydrate or polysaccharide)
        136989 CARBOHYDRATE
        157926 CARBOHYDRATES
        229667 CARBOHYDRATE
                   (CARBOHYDRATE OR CARBOHYDRATES)
          65584 POLYSACCHARIDE
          81844 POLYSACCHARIDES
         103380 POLYSACCHARIDE
                   (POLYSACCHARIDE OR POLYSACCHARIDES)
L7
             28 L6 AND (CARBOHYDRATE OR POLYSACCHARIDE)
=> d 17 1-28 ibib abs
```

1 "HENRY STEPHEN F"/AU

ANSWER 1 OF 28 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:666942 CAPLUS

DOCUMENT NUMBER: 147:425114

TITLE: Synthetic glycolipid modification of red blood cell

Frame, Tom; Carroll, Tim; Korchagina, Elena; AUTHOR(S):

Bovin, Nicolai; Henry, Stephen Immucor Inc., Atlanta, GA, USA

CORPORATE SOURCE:

SOURCE: Transfusion (Malden, MA, United States) (2007), 47(5),

876-882

CODEN: TRANAT; ISSN: 0041-1132 Blackwell Publishing, Inc.

DOCUMENT TYPE: Journal LANGUAGE: English

PUBLISHER:

Glycolipids have a natural ability to insert into red cell (RBC) membranes. Based on this concept the serol. of RBCs modified with synthetic analogs of blood group glycolipids (KODE technol.) was developed, which entails making synthetic glycolipid constructs engineered to have specific performance criteria. Such synthetic constructs can be made to express a potentially unlimited range of carbohydrate blood group determinants. Synthetic constructs incorporating A, B, acquired-B, and Lea blood group determinants were constructed and used to modify RBCs. Modified cells were assessed by routine serol. methods using a range of com. available monoclonal antibodies. RBCs modified with different concns. of synthetic glycolipids were able to give controllable serol. results. Synthetic A and B modified cells were able to be created to represent the serol. of "weak" subgroups. Specialized cells such as those bearing synthetic acquired-B antigen reacted as expected, but also exhibited extended features due to the cells bearing only specific antigen. Synthetic Lea-modified cells reacted as expected with anti-Lea reagents, but unexpectedly, were also able to detect the chemical anti-Leab specificity of serol. monoclonal anti-Leab reagents. RBCs can be created to express normal and novel carbohydrate profiles by inserting synthetic glycolipids into them. Such cells will be useful in creating specialized antigen panels and for quality control purposes.

THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS REFERENCE COUNT: 13 RECORD, ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 2 OF 28 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:154309 CAPLUS

DOCUMENT NUMBER: 146:336371

TITLE: Clustered carbohydrates as a target for natural killer cells: A model system

Kovalenko, Elena I.; Abakushina, Elena; Telford, AUTHOR(S):

William; Kapoor, Veena; Korchagina, Elena;

Khaidukov, Sergei; Molotkovskaya, Irina; Sapozhnikov,

Alexander; Vlaskin, Pavel; Bovin, Nicolai

CORPORATE SOURCE: Shemyakin and Ovchinnikov Institute of Bioorganic

Chemistry, Russian Academy of Sciences, Moscow,

117997, Russia

SOURCE: Histochemistry and Cell Biology (2007), 127(3),

313-326

CODEN: HCBIFP; ISSN: 0948-6143

PUBLISHER: Springer Journal DOCUMENT TYPE: LANGUAGE: English

Membrane-associated oligosaccharides are known to take part in interactions between natural killer (NK) cells and their targets and modulate NK cell activity. A model system was therefore developed using synthetic

glycoconjugates as tools to modify the carbohydrate pattern on NK target cell surfaces. NK cells were then assessed for function in response to synthetic glycoconjugates, using both cytolysis-associated caspase 6 activation measured by flow cytometry and IFN- γ production Lipophilic neoglycoconjugates were synthesized to provide their easy incorporation into the target cell membranes and to make carbohydrate residues available for cell-cell interactions. While incorporation was successful based on fluorescence monitoring, glycoconjugate incorporation did not evoke artifactual changes in surface antigen expression, and had no neg. effect on cell viability. Glycoconjugates contained Lex, sulfated Lex, and Ley sharing the common structure motif trisaccharide Lex were revealed to enhance cytotoxicity mediated specifically by CD16+CD56+ NK cells. The glycoconjugate effects were dependent on saccharide presentation in a polymeric form. Only polymeric, or clustered, but not monomeric glycoconjugates resulted in alteration of cytotoxicity in the authors' system, suggesting that appropriate presentation is critical for carbohydrate recognition and subsequent biol. effects.

REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 28 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:1042259 CAPLUS

DOCUMENT NUMBER: 143:339681

TITLE: Synthetic membrane anchors

INVENTOR(S): <u>Bovin</u>, <u>Nicolai</u>; <u>Gilliver</u>, <u>Lissa</u>;

Henry, Stephen; Korchagina, Elena

PATENT ASSIGNEE(S): Kiwi Ingenuity Limited, N. Z.

SOURCE: PCT Int. Appl., 109 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PA'	TENT	ΝΟ.			KIND DATE					ICAT										
WO	2005090368				A1															
	W:	ΑE,	AG,	AL,	AM,	AT,	ΑU,	AZ,	BA,	BB,	BG,	BR,	BW,	BY,	BZ,	CA,	CH,			
		CN,	CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FI,	GB,	GD,			
		GE,	GH,	GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KP,	KR,	KΖ,	LC,			
		LK,	LR,	LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NA,	NΙ,			
		NO,	NZ,	OM,	PG,	PH,	PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SK,	SL,	SM,			
		SY,	ТJ,	TM,	TN,	TR,	TT,	TZ,	UA,	UG,	US,	UZ,	VC,	VN,	YU,	ZA,	ZM,	ZW		
	RW:	BW,	GH,	GM,	KE,	LS,	MW,	MZ,	NA,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,			
		AZ,	BY,	KG,	KΖ,	MD,	RU,	ТJ,	TM,	ΑT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,			
		EE,	ES,	FΙ,	FR,	GB,	GR,	HU,	ΙE,	IS,	ΙΤ,	LT,	LU,	MC,	NL,	PL,	PT,			
		RO,	SE,	SI,	SK,	TR,	BF,	ВJ,	CF,	CG,	CI,	CM,	GΑ,	GN,	GQ,	GW,	ML,			
		MR,	NE,	SN,	TD,	ΤG														
AU	2005	2237	15		A1		2005	0929	AU 2005-223715						20050322					
CA	2560	781			A1		2005	0929	CA 2005-2560781						20050322					
EP	1735	323			A1	A1 20061227				EP 2005-722123						20050322				
	R:	ΑT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,	ES,	FI,	FR,	GB,	GR,	HU,	IE,			
		IS,	ΙΤ,	LI,	LT,	LU,	MC,	NL,	PL,	PT,	RO,	SE,	SI,	SK,	TR					
CN	1938		A		2007	0328	CN 2005-80009170													
JP	2007	5305	32		Τ		2007	1101		JP 2	007-	5049		20050322						
IN		Α		2007	0831		IN 2	006-	DN60	89		20061018								
US	2007		A1	A1 20070823				US 2007-593829					20070112							
CORIT	Y APP	.:						NZ 2	004-	5318	66		A 2	0040	322					
								NZ 2	005-	5379	41		A 2	0050	128					

OTHER SOURCE(S): MARPAT 143:339681

AB The invention relates to synthetic mols. such as modified glycolipids that spontaneously and stably incorporate into lipid by-layers, including cell membranes. Particularly, although not exclusively, the invention relates to the use of these mols. as synthetic membrane anchors or synthetic mol. constructs to effect qual. and quant. changes in the expression of cell surface antigens. Being able to effect qual. and/or quant. changes in the surface antigens expressed by a cell has diagnostic and therapeutic value. In a first aspect the invention consists in a mol. of the structure R-S2-L for use as a synthetic membrane anchor or in the preparation of synthetic mol. constructs where: R is a chemical

reactive functional group such as bis(N-hydroxysuccinimidyl), bis(4-nitrophenyl), bis(pentafluorophenyl), and bis(pentachlorophenyl); S2 is a spacer linking R to L such as -CO(CH2)3CO-, -CO(CH2)4CO-(adipate (Ad)), and -CO(CH2)5CO-; and L is a lipid selected from the group consisting of diacyl- and dialkylglycerolipids, including glycerophospholipids, and sphingosine derived diacyl- and dialkyllipids, including ceramide. In a second aspect, the invention consists in a synthetic mol. construct of the structure F-S1-S2-L where: F is an antigen selected from the group consisting of carbohydrates, proteins, lipids, lectins, avidins and biotin; S1-S2 is a spacer linking F to L; and L is a lipid selected from the group consisting of diacyl- and dialkylglycerolipids, including glycerophospholipids, and sphingosine derived diacyl- and dialkyllipids, including ceramide.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 4 OF 28 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:455781 CAPLUS

DOCUMENT NUMBER: 141:223907

TITLE: The Modification of Cell Surface with Lipophilic

Glycoconjugates and the Interaction of Modified Cells

with Natural Killer Cells

AUTHOR(S): Kovalenko, E. I.; Khirova, E. V.; Molotkovskaya, I.

M.; Ovchinnikova, T. V.; Sablina, M. A.; Sapozhnikov,

A. M.; Khaidukov, S. V.; Bovin, N. V.

CORPORATE SOURCE: Shemyakin-Ovchinnikov Institute of Bioorganic

Chemistry, Russian Academy of Sciences, Moscow,

117997, Russia

SOURCE: Russian Journal of Bioorganic Chemistry (Translation

of Bioorganicheskaya Khimiya) (2004), 30(3), 250-260

CODEN: RJBCET; ISSN: 1068-1620

PUBLISHER: MAIK Nauka/Interperiodica Publishing

DOCUMENT TYPE: Journal LANGUAGE: English

AB An exptl. model system involving the modification of carbohydrate
composition of the target cell surface with neoglycolipids was developed for studying the role of surface carbohydrates of target cells in the NK-cell-mediated cytotoxicity. The polymeric glycoconjugates of the Glyc-PAA-PEA and Glyc-PAA(Flu)-PEA types (where Glyc was an oligosaccharide residue, PAA poly(acrylamide) polymer, PEA the phosphatidylethanolamine residue, and Flu fluorescein residue) capable of incorporating into the cell membrane were synthesized. The optimum structures of neoglycoconjugates and the conditions for their incorporation into K562 and Raji cell lines, which differ in their sensitivity to the NK-cell-mediated lysis were selected. The mechanism of association of glycoconjugates with the plasma cell membrane and the kinetics

of their elimination from the cell surface were investigated using the fluorescent-labeled Glyc-PAA(Flu)-PEA derivs. The spatial accessibility of the carbohydrate ligands for the interaction with human NK cells was demonstrated. The target cells modified with the Lex trisaccharide were shown to be more sensitive to the cytotoxic effect of human NK cells than the intact cells.

REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 5 OF 28 CAPLUS COPYRIGHT 2008 ACS on STN L7

ACCESSION NUMBER: 2004:179410 CAPLUS

DOCUMENT NUMBER: 140:355485

Specificity of human anti-carbohydrate IgG TITLE:

antibodies as probed with polyacrylamide-based

glycoconjugates

Smorodin, E. P.; Kurtenkov, O. A.; Sergeyev, B. L.; AUTHOR(S):

Pazynina, G. V.; Bovin, N. V.

Institute of Experimental & Clinical Medicine, CORPORATE SOURCE:

Tallinn, 11619, Estonia

SOURCE: Glycoconjugate Journal (2004), 20(2), 83-89

CODEN: GLJOEW; ISSN: 0282-0080

PUBLISHER: Kluwer Academic Publishers

DOCUMENT TYPE: Journal LANGUAGE: English

The TF, Tn, and SiaTn glycotopes are frequently expressed in cancer-associated mucins. Antibodies to these glycotopes were found in human serum. A set of polyacrylamide (PAA)-based glycoconjugates was applied to the direct and competitive enzyme-linked immunosorbent assays (ELISA) to characterize the specificity of serum IgG antibodies. The anti-TF, -Tn and -SiaTn IgG were affinity purified from serum of cancer patients and characterized using PAA-conjugates and free saccharides. The anti-TF and -Tn antibodies were shown to be specific. The anti-TF IgG bound both $\mbox{Gal}\beta 1-3\mbox{GalNAc}\alpha-$ and $\mbox{Gal}\beta 1-3\mbox{GalNAc}\beta-\mbox{PAA,}$ the latter was three-four times more effective inhibitor of antibody binding. anti-Tn IgG reacted only with GalNAclpha-PAA. The anti-SiaTn IgG cross-reacted with Tn-PAA but SiaTn-PAA was five-six times more effective inhibitor in a competitive assay. The IC50 values for PAA-conjugates with the corresponding antibodies typically ranged from 2 to 5 + 10-8 M. The antibodies display a low specificity to mucin-type glycoconjugates in comparison with PAA-conjugates as was shown for mucins isolated from human malignant tumor tissues, ovine submaxillary mucin (OSM) and asialo-OSM. The unusual IgG-antibody specificity to $\text{GalNAc}\beta$ and $GalNAc\beta1-3GalNAc\beta$ ligands was found in human serum.

REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 6 OF 28 CAPLUS COPYRIGHT 2008 ACS on STN

2004:23220 CAPLUS ACCESSION NUMBER:

DOCUMENT NUMBER: 141:69871

TITLE: Glycochip: Multiarray for the study of

carbohydrate-binding proteins

AUTHOR(S): Galanina, O. E.; Mecklenburg, M.; Nifantiev, N. E.;

Pazynina, G. V.; Bovin, \underline{N} . \underline{V} . Shemyakin & Ovchinnikov Institute of Bioorganic CORPORATE SOURCE:

Chemistry, Russian Academy of Sciences, Moscow,

117997, Russia

Lab on a Chip (2003), 3(4), 260-265 SOURCE:

CODEN: LCAHAM; ISSN: 1473-0197

PUBLISHER: Royal Society of Chemistry

DOCUMENT TYPE: Journal LANGUAGE: English

AB Biotinylated glycoconjugates which were designed as oligosaccharides attached to 30 kDa polyacrylamide were coated on a microarray platform XNAonGOLD, which was developed earlier for an oligonucleotide assay. The specificity of antibodies to <u>carbohydrate antigens</u> was analyzed using the glyco-microarray. Comparison of the obtained results with those of common 96-well plate ELISA completely coincided with the found antibody specificities. However, parameters such as the anal.

sensitivity of the method and the amount of biotinylated material coated on

the microarray platform proved to be worse than expected.

REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 7 OF 28 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:509839 CAPLUS

DOCUMENT NUMBER: 140:159829

TITLE: Arrays of peptides and carbohydrate

molecules on self-assembled monolayers and their

application in blood serology

AUTHOR(S): Cieplik, Michael; Galanina, Oxana; Joos, Thomas;

Pfeiffer, Matthias; Klingel, Sven; Bovin, Nikolay; Nifant'ev, Nikolay; Mecklenburg, Michael; Videnov, Georgi; Ortigao, Flavio

CORPORATE SOURCE: Interactive Biotechnologie GmbH, Ulm, Germany

SOURCE: Peptides 2000, Proceedings of the European Peptide

Symposium, 26th, Montpellier, France, Sept. 10-15, 2000 (2001), Meeting Date 2000, 967-968. Editor(s): Martinez, Jean; Fehrentz, Jean-Alain. Editions EDK:

Paris, Fr.

CODEN: 69EDWK; ISBN: 2-84254-048-4

DOCUMENT TYPE: Conference LANGUAGE: English

AB Enzyme function and ligand-binding on arrays of peptides and carbohydrates were identified using a robust and universal platform for miniaturized assays. A highly ordered and addressable layer of streptavidin (SA) mols. was constructed via a self-assembling monolayer

of long-chain alkylthiol and a chemical interface with terminal biotin. The biochips are easy to handle, save reagent needs and time and have the necessary potential for parallel parameter processing. Samples of 50 μ l of mouse sera were tested against a set of 20 immobilized

carbohydrate antigens in less than one hour.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 8 OF 28 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:447486 CAPLUS

DOCUMENT NUMBER: 139:228222

TITLE: Binding Sites for Lewis Antigens Are

Expressed by Human Colon Cancer Cells and Negatively

Affect Their Migration

AUTHOR(S): Hittelet, Axel; Camby, Isabelle; Nagy, Nathalie;

Legendre, Hugues; Bronckart, Yves; Decaestecker, Christine; Kaltner, Herbert; Nifant'ev, Nikolay E.;

Bovin, Nicolai V.; Pector, Jean-Claude;

Salmon, Isabelle; Gabius, Hans-Joachim; Kiss, Robert;

Yeaton, Paul

CORPORATE SOURCE: Department of Gastroenterology, Ersamus University

Hospital, Brussels, 1070, Belg.

SOURCE: Laboratory Investigation (2003), 83(6), 777-787

CODEN: LAINAW; ISSN: 0023-6837

PUBLISHER: Lippincott Williams & Wilkins

DOCUMENT TYPE: Journal LANGUAGE: English

In colon cancer, endothelial cell selectins can promote tumor cell attachment via interactions with sialylated Lewis antigens present at the surface of tumor cells, thereby facilitating tumor cell arrest and transmigration into the extravascular space. However, it is not known whether Lewis antigens interact with colon tumor cells and modify their migration. Our aim was to detect the presence of binding sites on human tumor cells for Lewisa/x antigens and their sialylated derivs. in vitro and in vivo and to analyze their influence on migration of colon cancer cells. The immunocytochem. and histochem. levels of expression of the four Lewis antigens were quant. determined in four human colon cancer cell lines and in in vivo nude mice xenografts. The levels of expression of specific binding sites for these sugar epitopes were determined by synthetic neoglycoconjugates. The influence of binding of these carbohydrate ligands on cancer cell migration was quant. evaluated by computer-assisted phase-contrast videomicroscopy performed on Matrigel culture supports either left uncoated or coated with neoglycoconjugate presenting synthetic Lewisa, sialyl Lewisa, Lewisx, or sialyl Lewisx antigens. The influence of the calcium concentration in the culture medium on the Lewis antigen -mediated effects was checked. Human colon cancer cells expressed significant amts. of specific binding sites detected by the synthetic probes in addition to the oligosaccharide epitopes. The expression levels differed considerably between the four cell lines and between in vitro and in vivo specimens. Cell migration anal. revealed that the four Lewis antigens markedly decreased the levels of migration of the HCT-15 and LoVo cancer cells. This effect depends on the calcium concentration in the culture medium. Binding sites for Lewis epitopes are present on colon cancer cells. The functional relevance of these sites is indicated by the neg. influence on cell migration of a matrix containing the oligosaccharides as ligand parts.

REFERENCE COUNT: 55 THERE ARE 55 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 9 OF 28 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:967343 CAPLUS

DOCUMENT NUMBER: 138:383010

TITLE: Analysis of Binding of Mannosides in Relation to

Langerin (CD207) in Langerhans Cells of Normal and

Transformed Epithelia

AUTHOR(S): Plzak, Jan; Holikova, Zuzana; Dvorankova, Barbora;

Smetana, Karel, Jr.; Betka, Jan; Hercogova, Jana;

Saeland, Sem; Bovin, Nicolai V.; Gabius,

Hans-Joachim

CORPORATE SOURCE: Inst. Anatomy, Dep. Otorhinolaryngology, Charles

University, Prague, Czech Rep.

SOURCE: Histochemical Journal (2002), 34(5), 247-253

CODEN: HISJAE; ISSN: 0018-2214

PUBLISHER: Kluwer Academic Publishers

DOCUMENT TYPE: Journal LANGUAGE: English

AB Tandem-repeat C-type lectins (pattern-recognition receptors) with specificity for mannosides are intimately involved in antigen recognition, uptake, routing and presentation in macrophages and dendritic cells. In Langerhans cells, Langerin (CD207), a type-II transmembrane protein with a single C-type carbohydrate recognition domain attached to a heptad repeat in the neck region, which is likely to establish oligomers with an α -coiled-coil stalk, has been implicated

in endocytosis and the formation of Birbeck granules. The structure of Langerin harbors essential motifs for Ca2+-binding and sugar accommodation. Lectin activity has previously been inferred by diminished antibody binding to cells in the presence of the glycan ligand mannan. In view of the complexity of the C-type lectin/lectin-like network, it is unclear what role Langerin plays for Langerhans cells in binding mannosides. In order to reveal in frozen tissue sections to what extent mannose-binding activity co-localizes with Langerin, we have used a synthetic marker, i.e. a neoglycoprotein carrying mannose maxiclusters, as a histochem. ligand, and computer-assisted fluorescence monitoring in a double-labeling procedure. Mannoside-binding capacity was detected in normal epithelial cells. Double labeling ensured the unambiguous assessment of the binding of the neoglycoprotein in Langerhans cells. Light-microscopically, its localization profile resembled the pattern of immunohistochem. detection of Langerin. This result has implications for suggesting rigorous controls in histochem. anal. of this cell type, because binding of kit reagents, i.e. mannose-rich glycoproteins horseradish peroxidase or avidin, to Langerin (or a spatially closely associated lectin) could yield false-pos. signals. To show that recognition of carbohydrate ligands in dendritic cells is not restricted to mannose clusters, we have also documented binding of carrier-immobilized histo-blood group A trisaccharide, a ligand of galectin-3, which was not affected by the presence of a blocking antibody to Langerin. Remarkably, access to the carbohydrate recognition domain of Langerin appeared to be impaired in proliferatively active environments (malignancies, hair follicles), indicating presence of an endogenous ligand with high affinity to saturate the C-type lectin under these conditions.

REFERENCE COUNT: 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 10 OF 28 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:794873 CAPLUS

DOCUMENT NUMBER: 136:165111

TITLE: Human plasma trans-sialidase causes atherogenic

modification of low density lipoprotein

AUTHOR(S): Tertov, V. V.; Kaplun, V. V.; Sobenin, I. A.;

Boytsova, E. Yu.; Bovin, N. V.; Orekhov, A.

J

CORPORATE SOURCE: Cardiology Research Center, Institute of Experimental

Cardiology, Institute for Atherosclerosis Research

Ltd, Moscow, 121552, Russia

SOURCE: Atherosclerosis (Shannon, Ireland) (2001), 159(1),

103-115

CODEN: ATHSBL; ISSN: 0021-9150

PUBLISHER: Elsevier Science Ireland Ltd.

DOCUMENT TYPE: Journal LANGUAGE: English

AB In earlier studies we have found that incubation of low d. lipoprotein (LDL) with autologous blood plasma-derived serum leads to a loss of sialic acid from lipoprotein particles. In this study we demonstrated that sialic acid removed from LDL was transferred to glycoconjugates of lipoproteins, glycoproteins and sphingolipids of human serum. This showed that human serum contained the trans-sialidase activity. Gel-filtration chromatog. of human blood serum demonstrated the presence of trans-sialidase activity in lipoprotein subfractions as well as in lipoprotein-deficient serum. Trans-sialidase (about 65 kDa) was isolated from lipoprotein-deficient serum using affinity chromatog. carried out with Neu5Acα2-8Neu5Ac-Sepharose FF-6. Optimal pH values for the trans-sialidase were 3.0, 5.0 and 7.0. Calcium and magnesium ions

stimulated the enzyme activity at millimolar concns. Isolated enzyme can remove sialic acid from LDL, IDL, VLDL, and HDL particles (in decreasing rate order). Serum trans-sialidase transferred sialic acid from glycoconjugates of plasma proteins (fetuin, transferrin) and gangliosides (GM3, GD3, GM1, GD1a, GD1b). Sialylated glycoconjugates of human blood erythrocytes also served as substrate for serum trans-sialidase. We have found that sialic acid can also be removed from N- and O-linked glycans, sialylated Lex and Lea, oligosialic acids, and sphingolipid carbohydrate chains. The rate of sialic acid release decreased in the following order: $\alpha 2,6>\alpha 2,3>\alpha 2,8$. Transferred mol. of sialic acid can form $\alpha 2,6,\ \alpha 2,3$ and to a lesser degree α^2 ,8 linkage with galactose, N-acetyl-galactosamine or sialic acid of acceptors. The glycoconjugates of erythrocytes, lipoprotein particles, plasma proteins, neutral sphingolipids and gangliosides may serve as acceptors of transferred sialic acid. Trans-sialidase-treated native LDL becomes desialylated and then can induce cholesteryl ester accumulation in human aortic intimal smooth muscle cells. Thus, trans-sialidase may be involved in the early stages of atherogenesis characterized by foam cell formation.

REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 11 OF 28 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:552538 CAPLUS

DOCUMENT NUMBER: 135:318644

TITLE: Modified blood group A trisaccharide probes: synthesis

and interaction with antibodies

AUTHOR(S): Shipova, Ekaterina V.; Bovin, Nicolai V.

CORPORATE SOURCE: Shemyakin-Ovchinnikov Institute of Bioorganic

Chemistry, Russian Academy of Sciences, Moscow,

117871, Russia

SOURCE: Carbohydrate Letters (2001), 4(2), 85-90

CODEN: CLETEC; ISSN: 1073-5070

PUBLISHER: Harwood Academic Publishers

DOCUMENT TYPE: Journal LANGUAGE: English

OTHER SOURCE(S): CASREACT 135:318644

Three derivs. modified at the acetamide fragment of blood group trisaccharide A, $GalNAc\alpha 1-3(Fuc\alpha 1-2)Gal\beta-0$ -spacer were synthesized. In the first compound the amide oxygen was substituted for the sulfur atom. In the second compound the Me group was replaced with the trifluoromethyl moiety, and in the third compound the Me group was replaced with the hydrogen atom. The interaction of these probes with anti-A monoclonal antibodies gives the information about significance of trisaccharide Me and carbonyl groups for the formation of protein-

carbohydrates complex.
REFERENCE COUNT: 8 THERE ARE 8 CI

THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 12 OF 28 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:251381 CAPLUS

DOCUMENT NUMBER: 135:44969

TITLE: Natural hidden autoantibodies react with negatively

charged <u>carbohydrates</u> and xenoantigen Bdi

AUTHOR(S): Lekakh, I. V.; Bovin, N. V.; Bezyaeva, G.

P.; Poverenny, A. M.

CORPORATE SOURCE: Medical Radiology Research Center, Russian Academy of

Medical Sciences, Obninsk, 249020, Russia

SOURCE: Biochemistry (Moscow, Russian Federation) (Translation

of Biokhimiya (Moscow, Russian Federation)) (2001),

66(2), 163-167

CODEN: BIORAK; ISSN: 0006-2979

PUBLISHER: MAIK Nauka/Interperiodica Publishing

DOCUMENT TYPE: Journal LANGUAGE: English

AB Ig prepns. from sera of healthy donors contain polyspecific autoantibodies interacting with DNA and other charged antigens. These antibodies belong to the IgG class and can exist in the free or hidden state. The hidden antibody activity can be revealed after ion-exchange chromatog. on QAE-Sephadex A-50. Immunoenzyme assay was used to assess the interactions of both free and hidden antibodies with different carbohydrates. The hidden antibodies were only able to interact with different polyanionic carbohydrates and neutral xenoantigen Bdi.

REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 13 OF 28 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2000:763249 CAPLUS

DOCUMENT NUMBER: 134:40780

TITLE: Tk, a new colon tumor-associated antigen

resulting from altered O-glycosylation

AUTHOR(S): Meichenin, Marc; Rocher, Jezabel; Galanina, Oxana;

Bovin, Nicolai; Nifant'ev, Nikolay; Sherman,

Andrei; Cassagnau, Elisabeth; Heymann, Marie

Francoise; Bara, Jacques; Fraser, Robin H.; Le Pendu,

Jacques

CORPORATE SOURCE: INSERM U419, Institut de Biologie, Nantes, 44093, Fr.

SOURCE: Cancer Research (2000), 60(19), 5499-5507

CODEN: CNREA8; ISSN: 0008-5472

PUBLISHER: American Association for Cancer Research

DOCUMENT TYPE: Journal LANGUAGE: English

Erythrocyte polyagglutination antigens T and Tn are truncated O-glycan chains that are also carcinoma-associated antigens. The authors investigated whether Tk polyagglutination antigen could similarly be a carcinoma-associated marker and a target of immunotherapy. Monoclonal antibody LM389 was raised against Tk erythrocytes and tested by immunohistochem. LM389 strongly reacted with 48% human colorectal carcinomas. Labeling of normal tissues was visible on epithelial cells, mainly digestive, but was confined at a supranuclear level. Expression of the antigen on cloned human carcinoma cells correlated with sialosyl-Tn expression. O-Sialoglycoprotein endopeptidase treatment revealed that on carcinomas and cell lines, the epitope was present on O-glycans. Antibody specificity was determined using synthetic carbohydrates. Direct binding and inhibition studies indicated that LM389 best ligands were terminated by 2 branched N-acetylglucosamine units. Screening of murine cellular cell lines with LM389 allowed development of an exptl. model with Tk-pos. and -neq. cells in syngeneic BDIX rats. Vaccination of rats with Tk erythrocytes provided a protection against growth of rat Tk-pos., but not of Tk-neg., tumor cells in association with the development of antibodies. Thus, Tk polyagglutination antigen is a new colorectal carcinoma-associated antigen, absent from the normal cell surface, resulting from alteration of O-glycans biosynthesis and has potential as a target of immunotherapy.

REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

DOCUMENT NUMBER: 132:333259

TITLE: Binding sites for carrier-immobilized

carbohydrates in the kidney: implication for

the pathogenesis of Henoch-Schonlein purpura and/or

IqA nephropathy

AUTHOR(S): Sediva, Anna; Smetana, Karel, Jr.; Stejskal, Josef;

Bartunkova, Jirina; Liu, Fu-Tong; Bovin, Nicolai

V.; Gabius, Hans-Joachim

CORPORATE SOURCE: Institute of Immunology, Charles University, Prague,

CZ-150 18, Czech Rep.

SOURCE: Nephrology, Dialysis, Transplantation (1999), 14(12),

2885-2891

CODEN: NDTREA; ISSN: 0931-0509

PUBLISHER: Oxford University Press

DOCUMENT TYPE: Journal LANGUAGE: English

Henoch-Schonlein purpura is a common vasculitis of childhood affecting the skin, joints, gastrointestinal tract, and kidney. The mesangial deposition of IqA1 is the most critical factor for the prognosis of patients with this disease. The aberrant glycosylation of the IgAl subclass with the absence of terminally located galactose and presence of only lpha-N-acetylgalactosamine in O-linked oligosaccharides in the hinge region of IgA1 represents a prominent difference from the normal IgA1. These alterations prompt the supposition that the sugar part may guide IqA deposition by recognition of endogenous lectins on the mesangium. Owing to the limited knowledge about the expression of <u>carbohydrate</u> -binding sites in the human kidney the authors initiated the study of this aspect with a class of tools which are suitable to map the lectinome of cells. Employing biotinylated neoglycoconjugates, glycosaminoglycans, and sulfated polysaccharides they monitored the presence of accessible carbohydrate-binding sites in control kidneys represented by tumor-free areas of kidneys with Grawitz tumor and in biopsies from patients with Henoch-Schonlein purpura-associated IgA nephropathy. Using frozen sections, no expression of any tested carbohydrate-binding site(s) was observed in the endothelial and mesangial cells in glomeruli of the control kidneys as well as in the biopsies from Henoch-Schonlein purpura IqA nephropathic kidneys, in contrast to the tubules. The N-acetylgalactosamine-binding sites were expressed only in the inner layer of Bowman's capsule of 20% of glomeruli of the control kidney from one patient with Grawitz tumor, and one biopsy from a patient with Henoch-Schonlein purpura-associated IqA nephropathy. However, the macrophages in the glomeruli of patients with IqA nephropathy and interstitial macrophages from both studied groups, i.e. without and with IgA nephropathy, harbor capacity to recognize carrier-immobilized $\alpha\textsc{-N-acetylgalactosamine.}$ Access to this binding site for the neoligand conjugate can be blocked by the monoclonal antibody MEM-18 recognizing CD14 $\underline{\text{antigen}}$. The possibility for a participation of macrophage deposition of IqAl in mesangium via a lectin mechanism involving this binding capacity warrants further studies.

REFERENCE COUNT: 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 15 OF 28 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1998:178974 CAPLUS

DOCUMENT NUMBER: 128:269300

TITLE: Enzyme immunoassay kit for detecting antibodies to

group-specific antigen of group A

Streptococcus on the basis of conjugated

N-acetylglucosamine and its medical application

AUTHOR(S): Briko, N. I.; Bovin, N. V.; Shevelev, B. I.;

Dynga, L. O.; Blinnikova, E. I.; Kuksyuk, P. P.;

Myasoedova, S. I.; Ambrosov, I. V.; Filatov, N. N. Inst. Bioorg. Khim., Mosk. Med. Akad. im. Sechenova,

Moscow, Russia

SOURCE: Klinicheskaya Laboratornaya Diagnostika (1997), (9),

43 - 46

CODEN: KLDIES; ISSN: 0869-2084

PUBLISHER: Meditsina
DOCUMENT TYPE: Journal
LANGUAGE: Russian

CORPORATE SOURCE:

AB Enzyme immunoassay kit has been created for detecting antibodies to group A Streptococcus, based on N-acetylglucosamine. N-acetylglucosamine was selected as the group-specific determinant due to the structure of group A Streptococcus polysaccharide, in which this monosaccharide residue is lateral to the main polysaccharide chain and hence more available for antibodies. Water-soluble polyacrylamide is the carrier in this kit, for this carrier is stable and not prone to nonspecific reaction with proteins. In addition, the synthesis of polyacrylamide conjugates ensures reproducible results. Use of this kit permits the identification of group A streptococcal etiol. of the disease and thus carry out appropriate therapy; moreover, it helps predict the outcome of an acute streptococcal infection and detect the post-streptococcal complications in the early period of the disease.

L7 ANSWER 16 OF 28 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1998:2020 CAPLUS

DOCUMENT NUMBER: 128:100805

TITLE: Enzyme-linked immunosorbent assay of IqM antibodies to

Thomsen-Friedenreich (TF) hapten in oncodiagnostics:

comparison of data obtained with four

TF-glycoconjugates

AUTHOR(S): Smorodin, E. P.; Jansson, B.; Milyukhina, L.; Paaski,

G.; Bovin, N. V.; Ovchinnikova, T. V.;

Kurtenkov, O.

CORPORATE SOURCE: Institute of Experimental and Clinical Medicine,

Tallinn, Estonia

SOURCE: Bioorganicheskaya Khimiya (1997), 23(10), 795-799

CODEN: BIKHD7; ISSN: 0132-3423

PUBLISHER: MAIK Nauka
DOCUMENT TYPE: Journal
LANGUAGE: Russian

AB The level of IgM antibodies to the Thomsen-Friedenreich hapten (TF) relative to the total IgM level in the blood sera of gastric and breast carcinoma patients and healthy persons was determined using ELISA. The following TF glycoconjugates were tested: TF-polyacrylamide (PAA) (with

10mol.% of TF hapten $\mbox{Gal}\beta 1-3\mbox{GalNAc}\alpha a-O\,\mbox{(CH2)}\,\mbox{3NH}$ per number of

monomeric units in the polyacrylamide), TF-human serum albumin (HSA)

 $(Gal \beta 1-3Gal NAc \alpha a-O-p-C6H4-HSA containing approx. 15$

carbohydrate residues per HSA mol.), asialo- κ -

caseinoglycopeptide, and asialoglycophorin. The total IgM level was determined using antibodies to the μ -chain of human IgM. The statistically significant difference between cancer patients and healthy donors was revealed with two conjugates: TF-PAA and TF-HSA. In case of TF-PPA, the sensitivity of the assay was 75-83%, and the specificity was 77%. Thus, TF-PAA is the most suitable conjugate for measuring the level of serum anti-TF-IgM antibodies.

L7 ANSWER 17 OF 28 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1997:77974 CAPLUS

DOCUMENT NUMBER: 126:183292

TITLE: Polyacrylamide-based glycoconjugates as tools for

studying lectins, antigens and

glycosyltransferases in glycobiology, cytochemistry,

and histochemistry

AUTHOR(S): Bovin, N. V.

CORPORATE SOURCE: Inst. Bioorg. Khim. im. M. M. Shemyakina, RAN, Moscow,

117871, Russia

SOURCE: Bioorganicheskaya Khimiya (1996), 22(9), 643-663

CODEN: BIKHD7; ISSN: 0132-3423

PUBLISHER: MAIK Nauka

DOCUMENT TYPE: Journal; General Review

LANGUAGE: Russian

A review and discussion with 81 refs. about the synthesis, physicochem. AΒ characteristics, and applications for studying the carbohydrate -binding mols. of some analogs of human cell glycoconjugates, neoglycoconjugates. An approach to the synthesis of the polyacrylamide derivs. of carbohydrates based on the interaction of fully activated polyacrylic acid with ω -amino alkyl glycosides is described. It provides highly reproducible results, is simpler than previously known methods of synthesis of such derivs., and expands the range of synthetic possibilities because it can provide both the sugar-polymer type mols. and conjugates bearing various labels and effectors, sorbents, glyco surfaces, etc. In the first part of the review, the synthesis of polyacrylamide conjugates and their physicochem. properties are described. In the second part, the synthesis of some complex compds., such as pseudoglycoproteins, pseudomucins, glyco particles, and glyco surfaces, is outlined. Some examples of the application of the described conjugates in various fields of glycobiol. are also discussed. Prospects for further development of the presented approach in glycotechnol. and medicine are also described.

L7 ANSWER 18 OF 28 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1996:573782 CAPLUS

DOCUMENT NUMBER: 125:219140

TITLE: Receptors of selectins. 5. Monoclonal antibodies to

synthetic antigens SiaLea and SiaLex

AUTHOR(S): Vlasova, E. V.; Vorozhaikina, M. M.; Khral'tsova, L.

S.; Tuzikov, A. B.; Popova, I. S.; Tsvetkov, Yu. E.;

Nifant'ev, N. E.; Bovin, N. V.

CORPORATE SOURCE: Shemyakin-Ovchinnikov Inst. of Bioorganic Chem.,

Moscow, 117871, Russia

SOURCE: Bioorganicheskaya Khimiya (1996), 22(5), 358-365

CODEN: BIKHD7; ISSN: 0132-3423

PUBLISHER: MAIK Nauka
DOCUMENT TYPE: Journal
LANGUAGE: Russian

AB Five IgM class monoclonal antibodies (MAb) to the SiaLea tetrasaccharide, which is known as a serol. tumor marker CA 19.9, and 3 MAbs (1 of IgG3 and 2 of IgM class) to the SiaLex tetrasaccharide (differentiation antigen CD15s) were obtained against totally synthetic immunogens. The epitope specificity of the antibodies was determined using a wide range of oligosaccharides and their polyacrylamide conjugates. MAb 4E10 against SiaLea and MAb 4G5 to SiaLex were highly specific to the antigen predefined by immunization: they did not cross-react with either structurally and conformationally related oligosaccharides or with their disaccharide fragments. Two MAbs to SiaLea (D7 and E5B1) showed a weak binding to SiaLex. MAb CC1 recognized SiaLea and SiaLex almost equally, and MAb 5H9 to SiaLea cross-reacted with the non-sialylated form, the Lea trisaccharide. Two MAbs against SiaLex A3 and B11 bound to all carbohydrate structures containing the core disaccharide

 $Gal\beta-3(4)GlcNAc$.

ANSWER 19 OF 28 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1995:779880 CAPLUS

DOCUMENT NUMBER: 123:166995

TITLE: Purification of monoclonal antibodies to Ley and Led

carbohydrate antigens by

ion-exchange and thiophilic-adsorption chromatography AUTHOR(S):

Rapoport, Eugeniya M.; Zhigis, Larisa S.; Vlasova,

Ekaterina V.; Piskarev, Vladimir E.; Bovin,

Nikolay V.; Zubov, Vitaly P.

CORPORATE SOURCE: Shemyakin-Ovchinnikov Inst. Biorg. Chem., Russian

Acad. Sci., Moscow, 117871, Russia

Bioseparation (1995), 5(3), 141-6 SOURCE: CODEN: BISPE4; ISSN: 0923-179X

Kluwer

PUBLISHER: DOCUMENT TYPE: Journal LANGUAGE: English

The paper deals with convenient and fast method for purification of monoclonal AB antibodies (MAbs) to carbohydrate antigens Ley and Led from the cell culture and ascite fluid by ion-exchange chromatog. on S-Sepharose and salt-promoted chromatog. on a "thiophilic" adsorbent. One-step procedure on S-Sepharose of MAbs to Ley (IgG and IgM) provides significant purification (over 90% of contaminants were removed), while a purification factor for IgM to Led is much lower. Highly purified IgM to Led could be obtained by a two-step purification procedure including "thiophilic-adsorption" chromatog. and gel-filtration (90-98% of contaminants from the cell culture and ascite fluid were removed). prepns. of IgG and IgM retain their initial antibody activity.

L7 ANSWER 20 OF 28 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1995:716623 CAPLUS

DOCUMENT NUMBER: 123:141120

Monoclonal antibody LU-BCRU-G7 against a breast TITLE:

tumor-associated glycoprotein recognizes the

disaccharide $Gal \beta 1-3GlcNAc$

Rye, Phil D.; <u>Bovin</u>, <u>Nicolai</u> <u>V.</u>; Vlasova, AUTHOR(S):

Ekaterina V.; Walker, Rosemary A.

CORPORATE SOURCE: Inst. Cancer Research, Norwegian Radium Hospital,

Oslo, Norway

SOURCE: Glycobiology (1995), 5(4), 385-9

CODEN: GLYCE3; ISSN: 0959-6658

PUBLISHER: Oxford University Press

DOCUMENT TYPE: Journal LANGUAGE: English

The monoclonal antibody LU-BCRU-G7, that was generated by in vitro immunization, shows clin. value as a prognostic marker in early stage breast carcinoma. It has now been characterized with regard to its binding epitope. Using a recently described method based on the construction of N-substituted polyacrylamide (PAA) derivs. of carbohydrates (pseudopolysaccharides), the structure of the epitope for the monoclonal antibody LU-BCRU-G7 has been determined Competitive binding assays and inhibitory enzyme-linked immunosorbent assays (ELISAs) using these pseudopolysaccharides have shown the LU-BCRU-G7 epitope to be a disaccharide $Gal \beta 1-3GlcNAc$ (Lec; where Gal is D-galactose, Glc is D-glucose and GlcNAc is N-acetyl-D-glucosamine). Both galactose and N-acetyl glucosamine moieties are essential for binding. Substitution on C-2 or C-3 of the terminal galactose abolished binding, as did galactose- α terminated oligosaccharides. The galactose moiety alone, as expressed by the $Gal\beta$ -PAA conjugate, appeared to be a more

important feature of the epitope than the GlcNAc-PAA conjugate, which failed to bind or inhibit the LU-BCRU-G7 antibody. In the N-acetyl glucosamine moiety, binding was decreased but not eliminated by fucose substitution, as in Lea, or change in configuration of C-4, as in $Gal \beta 1-3GlcNAc$. Omission of the NAc group resulted in complete loss of activity. The tetrasaccharide lacto-N-tetraose, although containing the terminal Lec disaccharide, does not react with the antibody, suggesting conformational interference of the binding site. These findings show that the monoclonal antibody LU-BCRU-G7 recognizes a terminal isolactosamine fragment on a tumor-associated glycoprotein, which we have previously shown to be inversely related to survival in breast cancer.

ANSWER 21 OF 28 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1994:678461 CAPLUS

DOCUMENT NUMBER: 121:278461

TITLE: Monoclonal antibodies directed to the synthetic

carbohydrate antigen Ley

AUTHOR(S): Vlasova, E.V.; Byramova, N.E.; Tuzikov, A.B.; Zhigis,

L.S.; Rapoport, E.M.; Khaidukov, S.V.; Bovin,

N.V.

Shemyakin Institute of Bioorganic Chemistry, Moscow, CORPORATE SOURCE:

117871, Russia

SOURCE: Hybridoma (1994), 13(4), 295-301

CODEN: HYBRDY; ISSN: 0272-457X

DOCUMENT TYPE: Journal LANGUAGE: English

Tetrasaccharide Fuc α 1-2Gal β 1-4(Fuc α 1-3)GlcNAc is known as carbohydrate determinant of cancer- and AIDS-associated antigen Lewisy (Ley). Synthetic antigen to generate mouse monoclonal antibodies (MAbs) directed to Ley was prepared and constructed as a spacer-armed tetrasaccharide coupled with lipophilized polymer, Ley-PAA-PE, where PAA is a 30-kD polyacrylamide and PE is phosphatidylethanolamine. An efficient immune response was provided by using Ley-PAA-PE adsorbed on Salmonella minnesota. Pos. hybridomas were screened by ELISA (ELISA) using Lev-PAA as a coating agent. An inhibitory version of the same test system showed absolute specificity of two MAbs: only hapten Ley and Ley-PAA were strong inhibitors, in contrast to Leb, triand disaccharidic fragments of the mentioned tetrasaccharides, as well as their PAA-conjugates. MAbs obtained against synthetic antigen specifically stained the Ley (+) cell line A431.

ANSWER 22 OF 28 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1994:407074 CAPLUS

DOCUMENT NUMBER: 121:7074

Inhibition of monocyte phagocytosis related to TITLE: glycosylation of monoclonal antibody Fc fragment

AUTHOR(S): Kiryukhin, A. Yu.; Khramtsov, A. V.; Filatov, A. V.;

Bovin, N. V.; Solovyev, M. Ye.; Bachurin, P.

S.; Zemskov, V. M.

CORPORATE SOURCE: Inst. Immunol., Moscow, Russia

SOURCE: Immunologiya (Moscow, Russian Federation) (1993), (2),

CODEN: IMUNDA; ISSN: 0206-4952

Journal DOCUMENT TYPE: LANGUAGE: Russian

Monoclonal antibodies (Mab) T5G11 noticeably inhibited monocytic FcR-mediated functions (inhibition of erythrophagocytosis reached 60-90%) when immobilized on plastic. When Mab T5G11 was immobilized by protein A or anti-mouse IqG, the inhibition was cancelled. Fab fragments were unable to inhibit erythrophagocytosis either. Evaluation of Mab binding

with lectins Con A, PSL, PNA and WGA revealed enhanced T5G11 ability to bind lectin. Lectin-binding was inhibited in different degrees by water-soluble conjugates of monosaccharides with polyacrylamide. obtained by culturing hybridoma cells with tunicamycin, compared to controls, had a 40% reduction in lectin-binding capacity and inhibited monocytic phagocytosis by only 30%. Their antigen- and protein A-binding characteristics in this case were not affected. It is inferred that the above Mab may have a peculiar composition or/and structure of Fc carbohydrate chains responsible for the inhibitory effects on FcR-mediated functions of monocytes.

ANSWER 23 OF 28 CAPLUS COPYRIGHT 2008 ACS on STN

1994:239572 CAPLUS ACCESSION NUMBER:

DOCUMENT NUMBER: 120:239572

Synthesis of polymeric neoglycoconjugates based on TITLE:

N-substituted polyacrylamides

AUTHOR(S): Bovin, N. V.; Korchagina, E. Y.;

> Zemlyanukhina, T. V.; Byramova, N. E.; Galanina, O. E.; Zemlyakov, A. E.; Ivanov, A. E.; Zubov, V. P.;

Mochalova, L. V.

Shemyakin Inst. Bioorg. Chemi., Moscow, Russia CORPORATE SOURCE: SOURCE: Glycoconjugate Journal (1993), 10(2), 142-51

CODEN: GLJOEW; ISSN: 0282-0080

DOCUMENT TYPE: Journal LANGUAGE: English

Several types of polymeric glycoconjugates, N-substituted polyacrylamides,

have been synthesized by the reaction of activated polymers with

ω-aminoalkylglycosides: (i) (carbohydrate

-spacer)n-polyacrylamide, pseudopolysaccharides'; (ii) (

carbohydrate-spacer)n-phosphatidylethanolaminem-polyacrylamide, neoglycolipids, derivs. of phosphatidylethanolamine; (iii) (

carbohydrate-spacer)n-biotinm-polyacrylamide, biotinylated probes;

(i.v.) (carbohydrate-spacer) n-polyacrylamide-(macroporous

glass), affinity sorbents based on macroporous glass, covalently coated with polyacrylamide. An almost quant, yield in the conjugation reaction makes it possible to insert in the conjugate a predetd. quantity of the ligand(s). Pseudopolysaccharides proved to be a suitable form of antigen for activation of polystyrene and poly(vinyl chloride) plates (ELISA) and nitrocellulose membranes (dot blot), being advantageous

over traditional neoglycoproteins. Polyvalent glycolipids insert well in biol. membranes: their phys. properties, particularly solubility, can be changed in a desired direction. Biotinylated derivs. were used as probes for detection and anal. of lectins.

ANSWER 24 OF 28 CAPLUS COPYRIGHT 2008 ACS on STN L7

ACCESSION NUMBER: 1992:4880 CAPLUS

DOCUMENT NUMBER: 116:4880 ORIGINAL REFERENCE NO.: 116:975a,978a

TITLE: Epitope specificity of hemagglutinating monoclonal

anti-B antibodies

Galanina, O. E.; Deryugina, E. I.; Olovnikova, N. I.; AUTHOR(S):

Nosyrev, A. E.; Lapenkov, M. I.; Chekneva, N. B.;

Zemlyanukhina, T. V.; Korchagina, E. Yu.;

Bovin, N. V.

CORPORATE SOURCE: M. M. Shemyakin Inst. Bioorg. Chem., Moscow, USSR SOURCE:

Bioorganicheskaya Khimiya (1991), 17(9), 1177-87

CODEN: BIKHD7; ISSN: 0132-3423

DOCUMENT TYPE: Journal LANGUAGE: Russian

Fine epitope specificity of 10 monoclonal antibodies (MA) agglutinating

red blood cells B was studied. Three methods were used: 1) inhibition of MA binding to natural antigen by synthetic oligosaccharides (OS) and their polyacrylamide conjugates; 2) direct MA binding to a series of synthetic OS-polyacrylamide conjugates differing in carbohydrate epitope d.; and 3) direct MA binding to the affinity sorbents. All antibodies prefered trisaccharide B determinant $Gal\alpha 1-3$ (Fuc $\alpha 1-2$) Gal independently of their ability ot discriminate serol. subgroups of B erythrocytes (B, Bweak, B3). The correlation of the MAs epitope specificity with their ability to agglutinate red blood cells B subgroups is discussed. Of interest is that MAs which are able to agglutinate any B subgroups also bind the synthetic tetrasaccharide $Gal\alpha 1-3$ (Fuc $\alpha 1-2$) $Gal\beta 1-3GalNAc$, a B type 3 determinant.

L7 ANSWER 25 OF 28 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1988:148510 CAPLUS

DOCUMENT NUMBER: 108:148510

ORIGINAL REFERENCE NO.: 108:24355a,24358a

TITLE: Polyclonal antibodies to artificial Lewis A

antigen: production, characterization and their application to identification of

 $\underline{\text{carbohydrate}} \text{ determinants on cell surface of}$

mouse teratocarcinoma F-9

AUTHOR(S): Khorlin, A. Ya.; Bovin, N. V.; Gabrielyan,

N. D.; Gargul'yan, E. V.; Zatevakhina, G. V.;

Anfimova, M. L.

CORPORATE SOURCE: Inst. Bioorg. Khim. im. Shemyakina, Moscow, USSR

SOURCE: Immunologiya (Moscow, Russian Federation) (1987), (5),

65-9

CODEN: IMUNDA; ISSN: 0206-4952

DOCUMENT TYPE: Journal LANGUAGE: Russian

AB Polyclonal antibodies were obtained to artificial Lewis A <u>antigen</u> (Lea spacer-bovine albumin). The antibody specificity was characterized with the use of synthetic oligosaccharide-fragments of the <u>antigen</u> <u>carbohydrate</u> component. The antibodies were highly specific, as their interaction with <u>carbohydrate</u> determinants required the presence of 2 terminal monosaccharides: D-galactose and L-fucose. These antibodies reacted with artificial Lex <u>antigen</u>, which has theor. conformation affinity with Lea <u>antigen</u>. The antibodies interacted with natural <u>antigens</u> (soluble and membrane-bound). These antibodies were successfully used to detect SSEA-1 <u>antigen</u> on the cell surface of mouse teratocarcinoma F-9.

L7 ANSWER 26 OF 28 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1986:168703 CAPLUS

DOCUMENT NUMBER: 104:168703

ORIGINAL REFERENCE NO.: 104:26739a,26742a

TITLE: Artificial carbohydrate antigens.

Incorporation of the Lea trisaccharideinto polymers having an oligosaccharide → glycosylated spacer

→ <u>antigen</u> structure.

AUTHOR(S): Bovin, N. V.; Ivanova, I. A.; Khorlin, A.

Ya.

CORPORATE SOURCE: M. M. Shemyakin Inst. Bioorg. Chem., Moscow, USSR SOURCE: Bioorganicheskaya Khimiya (1985), 11(5), 662-70

CODEN: BIKHD7; ISSN: 0132-3423

DOCUMENT TYPE: Journal LANGUAGE: Russian

AB The Lea trisaccharide, $O-\alpha-D$ -Fucp- $(1\rightarrow 4)-O-[\beta-D$ -Galp- $(1\rightarrow 3)]-D$ -GlcNAc, was synthesized by selective β -

galactosylation of benzyl 2-acetamido-6-O-acetyl-2-deoxy- α -D-glucopyranoside with acetobromogalactose to give benzyl 2-acetamido-6-O-acetyl-3-O-(2,3,4,6-tetra-O-acetyl- β -D-galactopyranosyl)-2-deoxy- α -D-glucopyranoside which was further α -fucosylated by diphenylcyclopropenyl method or bromide-ion catalyzed reaction to give protected Lea trisaccharide. The deprotected trisaccharide was converted via acetylated oxazoline derivative into 3-(trifluoroacetamido)propyl β -trioside which was transformed into glycosides in which the Lea trisaccharide is connected with spacers containing amino-, azidocarbonyl-, or N-acryloyl groups. Conjugation of the spacered trisaccharide with proteins or copolymn. with acrylamide led to artificial Lea antigens.

L7 ANSWER 27 OF 28 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1986:146700 CAPLUS

DOCUMENT NUMBER: 104:146700

ORIGINAL REFERENCE NO.: 104:23187a,23190a

TITLE: Artificial peptide and <u>carbohydrate</u>

antigens. Immobilization of haptens and

adjuvant (MDP) on polyacrylamide

AUTHOR(S): Yurovskii, V. V.; Bovin, N. V.; Safonova, N.

G.; Vasilov, R. G.; Khorlin, A. Ya.

CORPORATE SOURCE: M. M. Shemyakin Inst. Bioorg. Chem., Moscow, USSR SOURCE: Bioorganicheskaya Khimiya (1986), 12(1), 100-5

CODEN: BIKHD7; ISSN: 0132-3423

DOCUMENT TYPE: Journal LANGUAGE: Russian

AB To study the influence of a polyacrylamide carrier on the immunogenic properties of peptide and oligosaccharide haptens, artificial antigens were prepared by conjugation of a synthetic hexapeptide (homologous to fragment 95-100 of the murine blood groups, Lea) with polyacrylamide. In some cases conjugates containing also a synthetic glycopeptide adjuvant, N-acetylmuramyl-L-alanyl-D-isoglutamine (MDP), were used. Antisera against haptens were obtained by immunization of BALB-c mice with the corresponding conjugates. By the use of ELISA it was shown that these antisera had a high binding titer (up to 10,000) to the corresponding hapten, and MDP immobilized on the same carrier as the hapten possessed a considerable immunostimulating activity. Thus, the usefulness of polyacrylamide for preparation of immunogenic artificial mols. bearing peptide and oligosaccharide haptens was demonstrated.

L7 ANSWER 28 OF 28 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1985:521257 CAPLUS

DOCUMENT NUMBER: 103:121257

ORIGINAL REFERENCE NO.: 103:19389a,19392a

TITLE: Immobilization of Lea trisaccharide and

muramyldipeptide on polyacrylamide. Incorporation of

adjuvant into artificial carbohydrate

antigens

AUTHOR(S): Khorlin, A. Ya.; Bovin, N. V.

CORPORATE SOURCE: M. M. Shemyakin Inst. Bioorg. Chem., Moscow, USSR SOURCE: Bioorganicheskaya Khimiya (1985), 11(5), 671-3

CODEN: BIKHD7; ISSN: 0132-3423

DOCUMENT TYPE: Journal LANGUAGE: Russian

GΙ

Fuc?1
$$\Rightarrow$$
4
GlcNAc?1 \Rightarrow 0(CH₂)3NHCOCH=CH₂
Gal?1 \Rightarrow 3

AB Artificial water-soluble <u>carbohydrate antigens</u> were prepared, either by reacting acrylamide with the β -[3- (acrylamido)propyl]glycoside of the Lea trisaccharide (I) (74:1 or 15:1) to form a copolymer containing the components in a 73:1 or 17:1 ratio, or by reacting acrylamide, I, and N1-(N-acetylmuramyl-L-alanyl-D-isoglutaminyl)-N6-acryloylhexamethylenediamine (II) (54:1:1) to produce a 3-component copolymer containing the components in a 58:1:1 ratio. The technique is recommended for preparation of artificial polyacrylamide-bound <u>antigens</u> having predictable adjuvant/hapten ratios.

=> file stng COST IN U.S. DOLLARS SINCE FILE TOTAL ENTRY SESSION FULL ESTIMATED COST 150.76 150.97 DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL ENTRY SESSION CA SUBSCRIBER PRICE -22.40-22.40

FILE 'STNGUIDE' ENTERED AT 13:26:40 ON 28 APR 2008 USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Apr 25, 2008 (20080425/UP).

=> file req COST IN U.S. DOLLARS SINCE FILE TOTAL ENTRY SESSION FULL ESTIMATED COST 1.14 152.11 DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL ENTRY SESSION CA SUBSCRIBER PRICE 0.00 -22.40

FILE 'REGISTRY' ENTERED AT 13:38:11 ON 28 APR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ${\tt ZIC/VINITI}$ data file provided by InfoChem.

STRUCTURE FILE UPDATES: 27 APR 2008 HIGHEST RN 1017684-24-0 DICTIONARY FILE UPDATES: 27 APR 2008 HIGHEST RN 1017684-24-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

Uploading C:\Program Files\Stnexp\Queries\10593829\elected.str

chain nodes :

7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 33 40 41 42 43 44 45 55 56 57 46 47 54 58 59

ring nodes :

1 2 3 4 5 6 34 35 36 37 38 39 48 49 50 51 52 53

chain bonds :

 $1 - 45 \quad 2 - 44 \quad 3 - 46 \quad 5 - 7 \quad 6 - 33 \quad 7 - 8 \quad 8 - 9 \quad 9 - 10 \quad 10 - 11 \quad 10 - 12 \quad 12 - 13 \quad 13 - 14 \quad 13 - 15$ $15-16 \quad 16-17 \quad 17-18 \quad 18-19 \quad 18-20 \quad 18-21 \quad 21-22 \quad 22-23 \quad 23-24 \quad 23-26 \quad 24-25 \quad 33-34$ 35-43 36-42 37-41 38-40 45-48 46-47 49-54 50-58 51-57 52-55 54-59 55-56

ring bonds :

 $1-2 \quad 1-6 \quad 2-3 \quad 3-4 \quad 4-5 \quad 5-6 \quad 34-35 \quad 34-39 \quad 35-36 \quad 36-37 \quad 37-38 \quad 38-39 \quad 48-49$

48-53 49-50 50-51 51-52 52-53

exact/norm bonds :

 $1-2 \quad 1-6 \quad 1-45 \quad 2-3 \quad 2-44 \quad 3-4 \quad 4-5 \quad 5-6 \quad 5-7 \quad 6-33 \quad 9-10 \quad 10-11 \quad 13-14 \quad 13-15$

 $17 - 18 \quad 18 - 19 \quad 18 - 20 \quad 18 - 21 \quad 21 - 22 \quad 23 - 26 \quad 24 - 25 \quad 33 - 34 \quad 34 - 35 \quad 34 - 39 \quad 35 - 36 \quad 35 - 43$

36-37 36-42 37-38 37-41 38-39 45 - 4846-47 48-49 48-53 49-50 49-54 50-51

50-58 51-52 51-57 52-53 54-59 55-56

exact bonds :

3-46 7-8 8-9 10-12 12-13 15-16 16-17 22-23 23-24 38-40 52-55

Match level:

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:CLASS 20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS 33:CLASS 34:Atom 35:Atom 36:Atom 37:Atom 38:Atom 39:Atom 40:CLASS 41:CLASS 42:CLASS 43:CLASS 44:CLASS 45:CLASS 46:CLASS 47:CLASS 48:Atom 49:Atom 50:Atom 51:Atom 52:Atom 53:Atom 54:CLASS 55:CLASS 56:CLASS 57:CLASS 58:CLASS 59:CLASS

=> d

L8 HAS NO ANSWERS

L8 STR

Structure attributes must be viewed using STN Express query preparation.

=> s 18

SAMPLE SEARCH INITIATED 13:38:34 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 5 TO ITERATE

100.0% PROCESSED 5 ITERATIONS 1 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 5 TO 234
PROJECTED ANSWERS: 1 TO 80

L9 1 SEA SSS SAM L8

=> d scan

L9 1 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN

IN 9-Octadecenoic acid (9Z)-, (1R)-1-[17-[[0-2-(acetylamino)-2-deoxy- α -D-galactopyranosyl-(1+3)-0-[6-deoxy- α -L-galactopyranosyl-(1+2)]- β -D-galactopyranosyl]oxy]-3-hydroxy-3-oxido-8,13-dioxo-2,4-dioxa-7,14-diaza-3-phosphaheptadec-1-yl]-1,2-ethanediyl ester, monopotassium salt (9CI)

MF C70 H126 N3 O25 P . K

Absolute stereochemistry. Double bond geometry as shown.

PAGE 1-A

● K

PAGE 1-B

O (CH₂)
$$7$$
 \overline{Z} (CH₂) 7 Me

R
O (CH₂) 7 \overline{Z} (CH₂) 7 Me

O (CH₂) 7 \overline{Z} (CH₂) 7

ALL ANSWERS HAVE BEEN SCANNED

=> d 18 full

L8 HAS NO ANSWERS

'FULL ' IS NOT A VALID STRUCTURE FORMAT KEYWORD

Structure Formats

SIA ---- Structure Image, Attributes, and map table if it contains data. (Default)

SIM ---- Structure IMage.

SAT ---- Structure ATtributes and map table if it contains data.

SCT ---- Structure Connection Table and map table if it contains data.

SDA ---- All Structure DAta (image, attributes, connection table and map table if it contains data).

NOS ---- NO Structure data.

ENTER STRUCTURE FORMAT (SIM), NOS:end

=> s 18 full

FULL SEARCH INITIATED 13:38:52 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 78 TO ITERATE

100.0% PROCESSED 78 ITERATIONS 8 ANSWERS

SEARCH TIME: 00.00.01

L10 8 SEA SSS FUL L8

=> file caplus

COST IN U.S. DOLLARS
SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST
178.36
330.47

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE
ENTRY
SESSION

CA SUBSCRIBER PRICE

0.00
-22.40

FILE 'CAPLUS' ENTERED AT 13:38:55 ON 28 APR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 28 Apr 2008 VOL 148 ISS 18 FILE LAST UPDATED: 27 Apr 2008 (20080427/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

=> s 110

L11 1 L10

=> d 111

- L11 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2008 ACS on STN
- AN 2005:1042259 CAPLUS
- DN 143:339681
- TI Synthetic membrane anchors
- IN Bovin, Nicolai; Gilliver, Lissa; Henry, Stephen; Korchagina, Elena
- PA Kiwi Ingenuity Limited, N. Z.
- SO PCT Int. Appl., 109 pp. CODEN: PIXXD2
- DT Patent
- LA English

FAN.CNT 1

	PA:	ΓENT	NO.			KIND DATE					APPL:	ICAT	ION 1	D					
ΡΙ	WO	2005 W:	AE, CN, GE, LK, NO, SY,	AG, CO, GH, LR, NZ, TJ,	CR, GM, LS, OM, TM,	A1 AM, CU, HR, LT, PG, TN,	AT, CZ, HU, LU, PH,	2005 AU, DE, ID, LV, PL, TT, MW,	0929 AZ, DK, IL, MA, PT,	BA, DM, IN, MD, RO, UA,	DZ, IS, MG, RU, UG,	BG, EC, JP, MK, SC, US,	BR, EE, KE, MN, SD, UZ,	BW, EG, KG, MW, SE, VC,	ES, KP, MX, SG, VN,	BZ, FI, KR, MZ, SK, YU,	GB, KZ, NA, SL, ZA,	CH, GD, LC, NI, SM, ZM,	ZW
	ΑIJ	2005	EE, RO, MR,	ES, SE, NE,	FI, SI,	FR, SK,	GB, TR, TG	RU, GR, BF,	HU, BJ,	IE, CF,	IS, CG,	IT, CI,	LT, CM,	LU, GA,	MC,	NL, GQ,	PL,	PT, ML,	
	CA EP	2560 1735 R:	781 323 AT, IS,	BE,	BG,	A1 A1 CH,	CY, LU,	2005 2006 CZ, MC,	0929 1227 DE, NL,	DK, PL,	CA 20 EP 20 EE, PT,	005- 005- ES, RO,	2560 7221 FI, SE,	GB, SK,	20050322 20050322 GR, HU, IE, TR				
PRAI	CN 1938325 JP 2007530532 IN 2006DN06089 US 20070197466 PRAI NZ 2004-531866							2007 2007 2007 2007 2004	1101 0831 0823		CN 20 JP 20 IN 20 US 20	007-	5049		20050322 20050322 20061018 20070112				
PRAI NZ 2004-531866 A 20040322 NZ 2005-537941 A 20050128 WO 2005-NZ52 W 20050322 OS MARPAT 143:339681 RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT																			
=> file stng COST IN U.S. DOLLARS SINCE FILE TOTAL ENTRY SESSION																			
FULL	FULL ESTIMATED COST											1.69 332.16							
	DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNT CA SUBSCRIBER PRICE											SIN	EN'	ILE TRY 0.00	S	TOTA ESSI -22	ON		
FILE USE : COPYI	IS S		СТ Т	O TH	E TE	RMS (OF Y	OUR	CUST	OMER	AGRI	EEME:	NT						

FILE CONTAINS CURRENT INFORMATION. LAST RELOADED: Apr 25, 2008 (20080425/UP).

=> file reg SINCE FILE TOTAL ENTRY SESSION 0.06 332.22 COST IN U.S. DOLLARS FULL ESTIMATED COST DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL ENTRY SESSION CA SUBSCRIBER PRICE 0.00 -22.40

FILE 'REGISTRY' ENTERED AT 13:39:13 ON 28 APR 2008 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ${\tt ZIC/VINITI}$ data file provided by InfoChem.

STRUCTURE FILE UPDATES: 27 APR 2008 HIGHEST RN 1017684-24-0 DICTIONARY FILE UPDATES: 27 APR 2008 HIGHEST RN 1017684-24-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>

Uploading C:\Program Files\Stnexp\Queries\10593829\broad.str

chain nodes :

7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26

ring nodes :

1 2 3 4 5 6

chain bonds :

 $5-7 \quad 7-8 \quad 8-9 \quad 9-10 \quad 10-11 \quad 10-12 \quad 12-13 \quad 13-14 \quad 13-15 \quad 15-16 \quad 16-17 \quad 17-18 \quad 18-19$

18-20 18-21 21-22 22-23 23-24 23-26 24-25

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6

exact/norm bonds :

 $1-2 \quad 1-6 \quad 2-3 \quad 3-4 \quad 4-5 \quad 5-6 \quad 5-7 \quad 9-10 \quad 10-11 \quad 13-14 \quad 13-15 \quad 17-18 \quad 18-19 \quad 18-20$

18-21 21-22 23-26 24-25

exact bonds :

7-8 8-9 10-12 12-13 15-16 16-17 22-23 23-24

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:CLASS 20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS

L12 STRUCTURE UPLOADED

=> d L12 HAS NO ANSWERS L12 STR

Structure attributes must be viewed using STN Express query preparation.

=> s 112

SAMPLE SEARCH INITIATED 13:39:37 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 12 TO ITERATE

100.0% PROCESSED 12 ITERATIONS 4 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 33 TO 447 PROJECTED ANSWERS: 4 TO 200

L13 4 SEA SSS SAM L12

=> s 112 full

FULL SEARCH INITIATED 13:39:43 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 269 TO ITERATE

100.0% PROCESSED 269 ITERATIONS 32 ANSWERS

SEARCH TIME: 00.00.01

L14 32 SEA SSS FUL L12

=> file caplus

COST IN U.S. DOLLARS SINCE FILE TOTAL ENTRY SESSION TULL ESTIMATED COST 178.36 510.58

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL ENTRY SESSION

CA SUBSCRIBER PRICE 0.00 -22.40

FILE 'CAPLUS' ENTERED AT 13:39:46 ON 28 APR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the

American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 28 Apr 2008 VOL 148 ISS 18 FILE LAST UPDATED: 27 Apr 2008 (20080427/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

=> s 114

L15 1 L14

=> d

- L15 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2008 ACS on STN
- AN 2005:1042259 CAPLUS
- DN 143:339681
- TI Synthetic membrane anchors
- IN Bovin, Nicolai; Gilliver, Lissa; Henry, Stephen; Korchagina, Elena
- PA Kiwi Ingenuity Limited, N. Z.
- SO PCT Int. Appl., 109 pp.
 - CODEN: PIXXD2
- DT Patent
- LA English

FAN.CNT 1

	PATENT NO.						KIND DATE			,	APPL	ICAT	DATE						
PI	WO	 O 2005090368					_	20050929			 WO 2	 005-:	 NZ52		2				
		W: AE, AG, AL,			AL,	AM,	ΑT,	AU,	ΑZ,	BA,	BB,	ВG,	BR,	BW,	BY,	BZ,	CA,	CH,	
			CN,	CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FI,	GB,	GD,	
			GE,	GH,	GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KP,	KR,	KΖ,	LC,	
			LK,	LR,	LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NA,	NΙ,	
			NO,	NZ,	OM,	PG,	PH,	PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SK,	SL,	SM,	
			SY,	ΤJ,	TM,	TN,	TR,	TT,	TZ,	UA,	UG,	US,	UZ,	VC,	VN,	YU,	ZA,	ZM,	ZW
		RW:	BW,	GH,	GM,	ΚE,	LS,	MW,	MZ,	NA,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,	
			AΖ,	BY,	KG,	KΖ,	MD,	RU,	ΤJ,	TM,	ΑT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	
			EE,	ES,	FΙ,	FR,	GB,	GR,	HU,	ΙE,	IS,	ΙΤ,	LT,	LU,	MC,	NL,	PL,	PT,	
			RO,	SE,	SI,	SK,	TR,	BF,	ВJ,	CF,	CG,	CI,	CM,	GΑ,	GN,	GQ,	GW,	ML,	
			MR,	NE,	SN,	TD,	ΤG												
	AU	J 2005223715				A1		2005	0929	AU 2005-223715						20050322			
	CA	2560		A1		2005	0929	CA 2005-2560781						20050322					
	ΕP	1735		A1	20061227			EP 2005-722123						20050322					
		R:	ΑT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,	ES,	FΙ,	FR,	GB,	GR,	HU,	ΙE,	
			IS,	ΙΤ,	LI,	LT,	LU,	MC,	NL,	PL,	PT,	RO,	SE,	SI,	SK,	TR			
	CN	1938	325			Α		2007	0328		CN 2	005-	8000		2	00503	322		
	JP	2007	5305	32		Τ		2007	1101	JP 2007-504907						2	00503	322	
	IN	2006	DN06	089		Α		2007	0831	IN 2006-DN6089						2	0061	018	
	US	2007	0197	466		A1		2007	0823	US 2007-593829									
PRAI	ΝZ	2004	-531	866		Α		2004	0322										
	NZ	2005	-537	941		Α		2005	0128										
	WO	2005	-NZ5	2		W		2005	0322										
OS	MAI	RPAT	143:	3396	81														
DE 01	ידיד	_	m r r			C 0.T	TDD		D D 3.7 (1)	_ ~		7 D T D	HOD	mrr T	0 55	0000			

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

(FILE 'HOME' ENTERED AT 13:24:42 ON 28 APR 2008) FILE 'CAPLUS' ENTERED AT 13:24:55 ON 28 APR 2008 E BOVIN NICOLAI/AU L1 306 S E1-E13 E GILLIVER LISSA/AU 2 S E2-E3 L2E HENRY STEPHEN/AU L3 36 S E3-E10 E KORCHAGINA ELENA/AU 42 S E1-E6 L4343 L1 OR L2 OR L3 OR L4 L5 71 S L5 AND ANTIGEN L6 28 L6 AND (CARBOHYDRATE OR POLYSACCHARIDE) L7 FILE 'STNGUIDE' ENTERED AT 13:26:40 ON 28 APR 2008 FILE 'REGISTRY' ENTERED AT 13:38:11 ON 28 APR 2008 STRUCTURE UPLOADED L8 L9 1 S L8 L10 8 S L8 FULL FILE 'CAPLUS' ENTERED AT 13:38:55 ON 28 APR 2008 L11 1 S L10 FILE 'STNGUIDE' ENTERED AT 13:39:08 ON 28 APR 2008 FILE 'REGISTRY' ENTERED AT 13:39:13 ON 28 APR 2008 L12 STRUCTURE UPLOADED L13 4 S L12 L14 32 S L12 FULL FILE 'CAPLUS' ENTERED AT 13:39:46 ON 28 APR 2008 L15 1 S L14 => ---Logging off of STN---=> Executing the logoff script... => LOG Y SINCE FILE TOTAL COST IN U.S. DOLLARS ENTRY SESSION FULL ESTIMATED COST 512.75 DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL ENTRY SESSION 0.00 -22.40 CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 13:40:50 ON 28 APR 2008